Trial · NCT04441931

A Study of LY3832479 (LY-CoV016) in Healthy Participants

NCT04441931, Phase 1, Completed, Eli Lilly and Company; results first posted 2021-12-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of LY3832479 (LY-CoV016) in Healthy Participants. Trials, record NCT04441931. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04441931

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of LY3832479 (LY-CoV016) in Healthy Participants
NCT number: NCT04441931
Status: Completed
Phases: Phase 1
Enrollment: 26 participants, actual
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: LY3832479, Placebo
First posted: 2020-06-22
Last updated: 2021-12-06
Results first posted: 2021-12-06

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Baseline through Follow-up (Week 12)	The number of participants with 1 or more SAEs assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Secondary	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC[0-∞]) of LY3832479	Day 1 (predose, end of infusion, 6 hours after start of infusion), 2, 3, 8, 15, 29, 43, 57, 85	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to infinity (AUC\[0-∞\]) of LY3832479.
Secondary	PK: Maximum Serum Concentration (Cmax) of LY3832479	Day 1 (predose, end of infusion, 6 hours after start of infusion), 2, 3, 8, 15, 29, 43, 57, 85	PK: Maximum Serum Concentration (Cmax) of LY3832479.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Baseline through Follow-up (Week 12)	All randomized participants who received at least one dose of study drug.	Participants	NUMBER
SECONDARY	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC[0-∞]) of LY3832479	Day 1 (predose, end of infusion, 6 hours after start of infusion), 2, 3, 8, 15, 29, 43, 57, 85	All randomized participants who received at least one dose of study drug and had evaluable PK data.	microgramsday per milliliter(ugday/mL)	GEOMETRIC_MEAN
SECONDARY	PK: Maximum Serum Concentration (Cmax) of LY3832479	Day 1 (predose, end of infusion, 6 hours after start of infusion), 2, 3, 8, 15, 29, 43, 57, 85	All randomized participants who received at least one dose of study drug and had evaluable PK data.	ug/mL	GEOMETRIC_MEAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	Pooled Placebo	0		Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	700 mg LY3832479 IV	0		Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	2800 mg LY3832479 IV	0		Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug	7000 mg LY3832479 IV	0		Participants
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC[0-∞]) of LY3832479	700 mg LY3832479 IV	4920	Geometric Coefficient of Variation 23	microgramsday per milliliter(ugday/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC[0-∞]) of LY3832479	2800 mg LY3832479 IV	22700	Geometric Coefficient of Variation 22	microgramsday per milliliter(ugday/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Infinity (AUC[0-∞]) of LY3832479	7000 mg LY3832479 IV	50800	Geometric Coefficient of Variation 33	microgramsday per milliliter(ugday/mL)
PK: Maximum Serum Concentration (Cmax) of LY3832479	700 mg LY3832479 IV	244	Geometric Coefficient of Variation 24	ug/mL
PK: Maximum Serum Concentration (Cmax) of LY3832479	2800 mg LY3832479 IV	1130	Geometric Coefficient of Variation 14	ug/mL
PK: Maximum Serum Concentration (Cmax) of LY3832479	7000 mg LY3832479 IV	2390	Geometric Coefficient of Variation 23	ug/mL

Source ClinicalTrials.gov

Participant flow16

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pooled Placebo	6
Overall Study	STARTED	700 mg LY3832479 IV	7
Overall Study	STARTED	2800 mg LY3832479 IV	7
Overall Study	STARTED	7000 mg LY3832479 IV	6
Overall Study	Received at Least One Dose of Study Drug	Pooled Placebo	6
Overall Study	Received at Least One Dose of Study Drug	700 mg LY3832479 IV	7
Overall Study	Received at Least One Dose of Study Drug	2800 mg LY3832479 IV	7
Overall Study	Received at Least One Dose of Study Drug	7000 mg LY3832479 IV	6
Overall Study	COMPLETED	Pooled Placebo	6
Overall Study	COMPLETED	700 mg LY3832479 IV	7

1 to 10 of 16Source ClinicalTrials.gov

See all 16 participant flow

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Dyspepsia	Gastrointestinal disorders	Pooled Placebo IV	1	6	1
other	Dyspepsia	Gastrointestinal disorders	700 mg LY3832479 IV	0	7	0
other	Dyspepsia	Gastrointestinal disorders	2800 mg LY3832479 IV	0	7	0
other	Dyspepsia	Gastrointestinal disorders	7000 mg LY3832479 IV	0	6	0
other	Covid-19	Infections and infestations	Pooled Placebo IV	1	6	1
other	Covid-19	Infections and infestations	700 mg LY3832479 IV	0	7	0
other	Covid-19	Infections and infestations	2800 mg LY3832479 IV	0	7	0
other	Covid-19	Infections and infestations	7000 mg LY3832479 IV	0	6	0
other	Arthropod sting	Injury, poisoning and procedural complications	Pooled Placebo IV	1	6	1
other	Arthropod sting	Injury, poisoning and procedural complications	700 mg LY3832479 IV	0	7	0

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pooled Placebo IV	0	6
Total, all-cause mortality	700 mg LY3832479 IV	0	7
Total, all-cause mortality	2800 mg LY3832479 IV	0	7
Total, all-cause mortality	7000 mg LY3832479 IV	0	6
Total, other adverse events	Pooled Placebo IV	3	6
Total, other adverse events	700 mg LY3832479 IV	2	7
Total, other adverse events	2800 mg LY3832479 IV	2	7
Total, other adverse events	7000 mg LY3832479 IV	0	6
Total, serious adverse events	Pooled Placebo IV	0	6
Total, serious adverse events	700 mg LY3832479 IV	0	7

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
34473343	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04441931

GET https://conductscience.org/api/trials/v1/NCT04441931/events?page=2

API reference For AI assistants